Presentation details the Company's acquisition strategy, revised 2026 pro forma revenue guidance of more than $50 ...
Aldeyra Therapeutics plunges after a third FDA CRL for reproxalap. Click here to read my most recent analysis of Aldeyra ...
STEPR is profitable, growing fast and the category leader in connected stair climbing; expected to generate more than ...
Presentation details the Company's acquisition strategy, revised 2026 pro forma revenue guidance of more than $50 million, and expected Adjusted EBITDA profitability in the fourth quarter of 2026TRNR ...
We look at a major retail divestment by a suburban mall REIT, an ambitious island transformation plan, a healthcare IPO that ...
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million ...
Forte Biosciences (FBRX) offers upside as FB102 demonstrates efficacy in both celiac disease and vitiligo, suggesting ...
STEPR is profitable, growing fast and the category leader in connected stair climbing; expected to generate more than $15 million in revenue in 2026 driven by increased US retailer demandPerformance-l ...
In 2025, Banijay Group recorded on a standalone basis (before Tipico and All3Media operations) revenue of €4.9 billion and Adjusted EBITDA of €961 million. Banijay Group is listed on Euronext ...
HCC Healthcare Pte. Ltd. (“HCC Healthcare” or the “Company”), a private company limited by shares incorporated in Singapore, today announced that it has signed a Business Combination Agreement (the ...
Stockhead on MSN
The Book of Genesis: Why the WA gold M&A story is only beginning
The most obvious gold tie-up on the ASX could thrust junior neighbours in one of Australia's most glittering districts into .
Some results have been hidden because they may be inaccessible to you
Show inaccessible results